Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
grade F 0.4471 -3.08% -0.01
BLRX closed down 3.08 percent on Friday, March 22, 2019, on 75 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical BLRX trend table...

Date Alert Name Type % Chg
Mar 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 22 Upper Bollinger Band Touch Strength 0.00%
Mar 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.08%
Mar 21 Pocket Pivot Bullish Swing Setup -3.08%
Mar 21 Upper Bollinger Band Walk Strength -3.08%
Mar 21 Above Upper BB Strength -3.08%
Mar 21 Upper Bollinger Band Touch Strength -3.08%
Mar 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.75%

Older signals for BLRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Health Biotechnology Pain Infectious Diseases Drug Discovery Autoimmune Diseases Clinical Trial Pharmacology Schizophrenia Acute Myeloid Leukemia Inflammatory Bowel Disease Design Of Experiments Clinical Research Central Nervous System Diseases Hematological Cancers Treatment Of Acute Myeloid Leukemia Biotechnology Companies Compugen Treatment Of Inflammatory Bowel Disease
Is BLRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.84
52 Week Low 0.38
Average Volume 1,474,684
200-Day Moving Average 0.7636
50-Day Moving Average 0.4859
20-Day Moving Average 0.4251
10-Day Moving Average 0.4351
Average True Range 0.0266
ADX 10.23
+DI 26.8509
-DI 16.5773
Chandelier Exit (Long, 3 ATRs ) 0.4
Chandelier Exit (Short, 3 ATRs ) 0.4748
Upper Bollinger Band 0.4531
Lower Bollinger Band 0.3971
Percent B (%b) 0.89
BandWidth 13.173371
MACD Line -0.0056
MACD Signal Line -0.0142
MACD Histogram 0.0086
Fundamentals Value
Market Cap 42.75 Million
Num Shares 95.6 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -1.60
Price-to-Sales 0.00
Price-to-Book 1.78
PEG Ratio 0.18
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.50
Resistance 3 (R3) 0.50 0.49 0.49
Resistance 2 (R2) 0.49 0.48 0.49 0.49
Resistance 1 (R1) 0.47 0.47 0.46 0.46 0.48
Pivot Point 0.45 0.45 0.45 0.45 0.45
Support 1 (S1) 0.43 0.44 0.43 0.43 0.41
Support 2 (S2) 0.42 0.43 0.42 0.41
Support 3 (S3) 0.40 0.42 0.40
Support 4 (S4) 0.39